合成生物学与绿色生物制造·2026-03-02 04:06Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] - The article outlines the basic information, main business composition, ongoing projects, and development strategies of ten leading companies in the bio-manufacturing industry, including Kasei Biotech, Huaheng Biotech, and others [2] Group 1: Kasei Biotech (688065) - Kasei Biotech achieved a revenue of 3.295 billion yuan in 2025, marking an 11.41% year-on-year increase, with a net profit of 566 million yuan, up 15.7% [3] - The main business composition includes synthetic bio-materials, with long-chain dicarboxylic acids generating 2.67 billion yuan in revenue, accounting for 90.26% of total income [6] - Ongoing projects focus on bio-manufacturing research, including the development of fermentation technology for bio-based materials and high-throughput microbial screening systems [7][8] Group 2: Huaheng Biotech (688639) - Huaheng Biotech plans to list in Hong Kong, with projected revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - The main business composition includes amino acids, contributing 1.509 billion yuan, and vitamins, contributing 207 million yuan, with a significant portion of revenue coming from overseas [11] - Ongoing projects include optimizing amino acid production strains and developing high-purity amino acid removal processes [12][13] Group 3: Huadong Medicine (000963) - Huadong Medicine expects a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [15] - The industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [15] - The company has initiated 393 research projects in the industrial microbiology field, focusing on xRNA materials and health-related products [19] Group 4: Meihua Biotech (600873) - Meihua Biotech reported a revenue of 25.069 billion yuan in 2024, a 9.69% decrease, with a net profit of 2.740 billion yuan, down 13.85% [28] - The company focuses on amino acid production and has developed a comprehensive ecosystem including animal nutrition and pharmaceutical-grade amino acids [27] - Research and development investments reached 733 million yuan in 2024, emphasizing the development of new technologies and strains [31] Group 5: Chuan Ning Biotech (301301) - Chuan Ning Biotech achieved a revenue of 5.758 billion yuan in 2024, a 19.38% increase, with a net profit of 1.400 billion yuan, up 48.88% [36] - The main business composition is primarily in pharmaceutical manufacturing, with a significant portion of revenue from pharmaceutical intermediates [38] - The company has established a commercial system integrating product selection, research, and large-scale production [37]